APO Research

APO RESEARCH · REPORT

Furazolidone

Selected research

Market Outlook & Growth Opportunities

Global Furazolidone Market Outlook and Growth Opportunities 2026

Market perspective

The global Furazolidone market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Furazolidone is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Furazolidone is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Furazolidone is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Furazolidone market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Furazolidone market include Becton, Dickinson and Company (BD), Daiichi Sankyo, Ferring, Geo-Med, GrÜNenthal Gmbh, Keyfarm, KPL Pharma, Marvi and Standpharm, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Furazolidone market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Furazolidone and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Furazolidone sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Furazolidone market size, projected growth trends, production technologies, key applications, and end-use industries.

Furazolidone Segment by Company

Becton, Dickinson and Company (BD)

Daiichi Sankyo

Ferring

Geo-Med

GrÜNenthal Gmbh

Keyfarm

KPL Pharma

Marvi

Standpharm

Teva

Furazolidone Segment by Type

Pharma Grade

Industrial Grade

Others

Furazolidone Segment by Application

Pharmacy

Industry

Furazolidone Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Furazolidone status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Furazolidone market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Furazolidone significant trends, drivers, influence factors in global and regions.

6. To analyze Furazolidone competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Furazolidone market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Furazolidone and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Furazolidone.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Furazolidone market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Furazolidone industry.

Chapter 3: Detailed analysis of Furazolidone manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Furazolidone in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Furazolidone in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Furazolidone Industry Trends Table 2. Furazolidone Industry Drivers Table 3. Furazolidone Industry Opportunities and Challenges Table 4. Furazolidone Industry Restraints Table 5. Global Furazolidone Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Furazolidone Revenue Share by Company (2021-2026) Table 7. Global Furazolidone Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Furazolidone Sales Volume Share by Company (2021-2026) Table 9. Global Furazolidone Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Furazolidone Company Ranking, (2024-2026) & (USD Million) Table 11. Global Furazolidone Key Company Manufacturing Base & Headquarters Table 12. Global Furazolidone Company, Product Type & Application Table 13. Global Furazolidone Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Furazolidone by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Pharma Grade Table 18. Significant Companies of Industrial Grade Table 19. Significant Companies of Others Table 20. Global Furazolidone Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 21. Global Furazolidone Sales Volume by Type (2021-2026) & (K Units) Table 22. Global Furazolidone Sales Volume by Type (2027-2032) & (K Units) Table 23. Global Furazolidone Sales Volume Share by Type (2021-2026) Table 24. Global Furazolidone Sales Volume Share by Type (2027-2032) Table 25. Global Furazolidone Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Furazolidone Sales Value by Type (2021-2026) & (US$ Million) Table 27. Global Furazolidone Sales Value by Type (2027-2032) & (US$ Million) Table 28. Global Furazolidone Sales Value Share by Type (2021-2026) Table 29. Global Furazolidone Sales Value Share by Type (2027-2032) Table 30. Significant Companies of Pharmacy Table 31. Significant Companies of Industry Table 32. Global Furazolidone Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 33. Global Furazolidone Sales Volume by Application (2021-2026) & (K Units) Table 34. Global Furazolidone Sales Volume by Application (2027-2032) & (K Units) Table 35. Global Furazolidone Sales Volume Share by Application (2021-2026) Table 36. Global Furazolidone Sales Volume Share by Application (2027-2032) Table 37. Global Furazolidone Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Furazolidone Sales Value by Application (2021-2026) & (US$ Million) Table 39. Global Furazolidone Sales Value by Application (2027-2032) & (US$ Million) Table 40. Global Furazolidone Sales Value Share by Application (2021-2026) Table 41. Global Furazolidone Sales Value Share by Application (2027-2032) Table 42. Global Furazolidone Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 43. Global Furazolidone Sales by Region (2021-2026) & (K Units) Table 44. Global Furazolidone Sales Market Share by Region (2021-2026) Table 45. Global Furazolidone Sales by Region (2027-2032) & (K Units) Table 46. Global Furazolidone Sales Market Share by Region (2027-2032) Table 47. Global Furazolidone Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Furazolidone Sales Value by Region (2021-2026) & (US$ Million) Table 49. Global Furazolidone Sales Value Share by Region (2021-2026) Table 50. Global Furazolidone Sales Value by Region (2027-2032) & (US$ Million) Table 51. Global Furazolidone Sales Value Share by Region (2027-2032) Table 52. Global Furazolidone Market Average Price (US$/Unit) by Region (2021-2026) Table 53. Global Furazolidone Market Average Price (US$/Unit) by Region (2027-2032) Table 54. Global Furazolidone Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 55. Global Furazolidone Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 56. Global Furazolidone Sales by Country (2021-2026) & (K Units) Table 57. Global Furazolidone Sales Market Share by Country (2021-2026) Table 58. Global Furazolidone Sales by Country (2027-2032) & (K Units) Table 59. Global Furazolidone Sales Market Share by Country (2027-2032) Table 60. Global Furazolidone Sales Value by Country (2021-2026) & (US$ Million) Table 61. Global Furazolidone Sales Value Market Share by Country (2021-2026) Table 62. Global Furazolidone Sales Value by Country (2027-2032) & (US$ Million) Table 63. Global Furazolidone Sales Value Market Share by Country (2027-2032) Table 64. Becton, Dickinson and Company (BD) Company Information Table 65. Becton, Dickinson and Company (BD) Business Overview Table 66. Becton, Dickinson and Company (BD) Furazolidone Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 67. Becton, Dickinson and Company (BD) Furazolidone Product Portfolio Table 68. Becton, Dickinson and Company (BD) Recent Development Table 69. Daiichi Sankyo Company Information Table 70. Daiichi Sankyo Business Overview Table 71. Daiichi Sankyo Furazolidone Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 72. Daiichi Sankyo Furazolidone Product Portfolio Table 73. Daiichi Sankyo Recent Development Table 74. Ferring Company Information Table 75. Ferring Business Overview Table 76. Ferring Furazolidone Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 77. Ferring Furazolidone Product Portfolio Table 78. Ferring Recent Development Table 79. Geo-Med Company Information Table 80. Geo-Med Business Overview Table 81. Geo-Med Furazolidone Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 82. Geo-Med Furazolidone Product Portfolio Table 83. Geo-Med Recent Development Table 84. GrÜNenthal Gmbh Company Information Table 85. GrÜNenthal Gmbh Business Overview Table 86. GrÜNenthal Gmbh Furazolidone Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 87. GrÜNenthal Gmbh Furazolidone Product Portfolio Table 88. GrÜNenthal Gmbh Recent Development Table 89. Keyfarm Company Information Table 90. Keyfarm Business Overview Table 91. Keyfarm Furazolidone Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. Keyfarm Furazolidone Product Portfolio Table 93. Keyfarm Recent Development Table 94. KPL Pharma Company Information Table 95. KPL Pharma Business Overview Table 96. KPL Pharma Furazolidone Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. KPL Pharma Furazolidone Product Portfolio Table 98. KPL Pharma Recent Development Table 99. Marvi Company Information Table 100. Marvi Business Overview Table 101. Marvi Furazolidone Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 102. Marvi Furazolidone Product Portfolio Table 103. Marvi Recent Development Table 104. Standpharm Company Information Table 105. Standpharm Business Overview Table 106. Standpharm Furazolidone Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 107. Standpharm Furazolidone Product Portfolio Table 108. Standpharm Recent Development Table 109. Teva Company Information Table 110. Teva Business Overview Table 111. Teva Furazolidone Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 112. Teva Furazolidone Product Portfolio Table 113. Teva Recent Development Table 114. Key Raw Materials Table 115. Raw Materials Key Suppliers Table 116. Furazolidone Distributors List Table 117. Furazolidone Customers List Table 118. Research Programs/Design for This Report Table 119. Authors List of This Report Table 120. Secondary Sources Table 121. Primary Sources List of Figures Figure 1. Furazolidone Product Image Figure 2. Global Furazolidone Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Furazolidone Sales Value (2021-2032) & (US$ Million) Figure 4. Global Furazolidone Sales (2021-2032) & (K Units) Figure 5. Global Furazolidone Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Furazolidone Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Pharma Grade Image Figure 10. Industrial Grade Image Figure 11. Others Image Figure 12. Global Furazolidone Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 13. Global Furazolidone Sales Volume Share 2021 VS 2025 VS 2032 Figure 14. Global Furazolidone Sales Volume Share by Type (2021-2032) Figure 15. Global Furazolidone Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Furazolidone Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Furazolidone Sales Value Share by Type (2021-2032) Figure 18. Pharmacy Image Figure 19. Industry Image Figure 20. Global Furazolidone Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 21. Global Furazolidone Sales Volume Share 2021 VS 2025 VS 2032 Figure 22. Global Furazolidone Sales Volume Share by Application (2021-2032) Figure 23. Global Furazolidone Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Furazolidone Sales Value Share 2021 VS 2025 VS 2032 Figure 25. Global Furazolidone Sales Value Share by Application (2021-2032) Figure 26. Global Furazolidone Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 27. Global Furazolidone Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 28. Global Furazolidone Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 29. Global Furazolidone Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 30. North America Furazolidone Sales Value (2021-2032) & (US$ Million) Figure 31. North America Furazolidone Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Europe Furazolidone Sales Value (2021-2032) & (US$ Million) Figure 33. Europe Furazolidone Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Asia-Pacific Furazolidone Sales Value (2021-2032) & (US$ Million) Figure 35. Asia-Pacific Furazolidone Sales Value Share by Country (%), 2025 VS 2032 Figure 36. South America Furazolidone Sales Value (2021-2032) & (US$ Million) Figure 37. South America Furazolidone Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Middle East & Africa Furazolidone Sales Value (2021-2032) & (US$ Million) Figure 39. Middle East & Africa Furazolidone Sales Value Share by Country (%), 2025 VS 2032 Figure 40. USA Furazolidone Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. USA Furazolidone Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. USA Furazolidone Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Canada Furazolidone Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Canada Furazolidone Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Canada Furazolidone Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Mexico Furazolidone Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Mexico Furazolidone Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Mexico Furazolidone Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Germany Furazolidone Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Germany Furazolidone Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Germany Furazolidone Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. France Furazolidone Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. France Furazolidone Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. France Furazolidone Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. U.K. Furazolidone Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. U.K. Furazolidone Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. U.K. Furazolidone Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Italy Furazolidone Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Italy Furazolidone Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Italy Furazolidone Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Spain Furazolidone Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Spain Furazolidone Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Spain Furazolidone Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Russia Furazolidone Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Russia Furazolidone Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Russia Furazolidone Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Netherlands Furazolidone Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Netherlands Furazolidone Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Netherlands Furazolidone Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Nordic Countries Furazolidone Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Nordic Countries Furazolidone Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Nordic Countries Furazolidone Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. China Furazolidone Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. China Furazolidone Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. China Furazolidone Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Japan Furazolidone Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Japan Furazolidone Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Japan Furazolidone Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. South Korea Furazolidone Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. South Korea Furazolidone Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. South Korea Furazolidone Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. India Furazolidone Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. India Furazolidone Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. India Furazolidone Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Australia Furazolidone Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Australia Furazolidone Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Australia Furazolidone Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Southeast Asia Furazolidone Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Southeast Asia Furazolidone Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Southeast Asia Furazolidone Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Brazil Furazolidone Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Brazil Furazolidone Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Brazil Furazolidone Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Argentina Furazolidone Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Argentina Furazolidone Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Argentina Furazolidone Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Chile Furazolidone Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Chile Furazolidone Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Chile Furazolidone Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Colombia Furazolidone Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Colombia Furazolidone Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Colombia Furazolidone Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Peru Furazolidone Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Peru Furazolidone Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Peru Furazolidone Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Saudi Arabia Furazolidone Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Saudi Arabia Furazolidone Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Furazolidone Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Israel Furazolidone Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Israel Arabia Furazolidone Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Israel Arabia Furazolidone Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. UAE Furazolidone Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. UAE Furazolidone Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. UAE Furazolidone Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Turkey Furazolidone Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Turkey Furazolidone Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Turkey Furazolidone Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Iran Furazolidone Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Iran Furazolidone Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Iran Furazolidone Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Egypt Furazolidone Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Egypt Furazolidone Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Egypt Furazolidone Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Furazolidone Value Chain Figure 125. Manufacturing Cost Structure Figure 126. Furazolidone Sales Mode & Process Figure 127. Direct Comparison with Distribution Share Figure 128. Distributors Profiles Figure 129. Years Considered Figure 130. Research Process Figure 131. Key Executives Interviewed

Scope & coverage.

Types
  • Pharma Grade
  • Industrial Grade
  • Others
Applications
  • Pharmacy
  • Industry
Companies covered
  • Becton, Dickinson and Company (BD)
  • Daiichi Sankyo
  • Ferring
  • Geo-Med
  • GrÜNenthal Gmbh
  • Keyfarm
  • KPL Pharma
  • Marvi
  • Standpharm
  • Teva

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Furazolidone Sales Value (2021-2032)
  4. 1.2.2 Global Furazolidone Sales Volume (2021-2032)
  5. 1.2.3 Global Furazolidone Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Furazolidone Market Dynamics
  1. 2.1 Furazolidone Industry Trends
  2. 2.2 Furazolidone Industry Drivers
  3. 2.3 Furazolidone Industry Opportunities and Challenges
  4. 2.4 Furazolidone Industry Restraints
3 Furazolidone Market by Company
  1. 3.1 Global Furazolidone Company Revenue Ranking in 2025
  2. 3.2 Global Furazolidone Revenue by Company (2021-2026)
  3. 3.3 Global Furazolidone Sales Volume by Company (2021-2026)
  4. 3.4 Global Furazolidone Average Price by Company (2021-2026)
  5. 3.5 Global Furazolidone Company Ranking (2024-2026)
  6. 3.6 Global Furazolidone Company Manufacturing Base and Headquarters
  7. 3.7 Global Furazolidone Company Product Type and Application
  8. 3.8 Global Furazolidone Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Furazolidone Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Furazolidone Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Furazolidone Market by Type
  1. 4.1 Furazolidone Type Introduction
  2. 4.1.1 Pharma Grade
  3. 4.1.2 Industrial Grade
  4. 4.1.3 Others
  5. 4.2 Global Furazolidone Sales Volume by Type
  6. 4.2.1 Global Furazolidone Sales Volume by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Furazolidone Sales Volume by Type (2021-2032)
  8. 4.2.3 Global Furazolidone Sales Volume Share by Type (2021-2032)
  9. 4.3 Global Furazolidone Sales Value by Type
  10. 4.3.1 Global Furazolidone Sales Value by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Furazolidone Sales Value by Type (2021-2032)
  12. 4.3.3 Global Furazolidone Sales Value Share by Type (2021-2032)
5 Furazolidone Market by Application
  1. 5.1 Furazolidone Application Introduction
  2. 5.1.1 Pharmacy
  3. 5.1.2 Industry
  4. 5.2 Global Furazolidone Sales Volume by Application
  5. 5.2.1 Global Furazolidone Sales Volume by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Furazolidone Sales Volume by Application (2021-2032)
  7. 5.2.3 Global Furazolidone Sales Volume Share by Application (2021-2032)
  8. 5.3 Global Furazolidone Sales Value by Application
  9. 5.3.1 Global Furazolidone Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Furazolidone Sales Value by Application (2021-2032)
  11. 5.3.3 Global Furazolidone Sales Value Share by Application (2021-2032)
6 Furazolidone Regional Sales and Value Analysis
  1. 6.1 Global Furazolidone Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Furazolidone Sales by Region (2021-2032)
  3. 6.2.1 Global Furazolidone Sales by Region: 2021-2026
  4. 6.2.2 Global Furazolidone Sales by Region (2027-2032)
  5. 6.3 Global Furazolidone Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Furazolidone Sales Value by Region (2021-2032)
  7. 6.4.1 Global Furazolidone Sales Value by Region: 2021-2026
  8. 6.4.2 Global Furazolidone Sales Value by Region (2027-2032)
  9. 6.5 Global Furazolidone Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Furazolidone Sales Value (2021-2032)
  12. 6.6.2 North America Furazolidone Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Furazolidone Sales Value (2021-2032)
  15. 6.7.2 Europe Furazolidone Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Furazolidone Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Furazolidone Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Furazolidone Sales Value (2021-2032)
  21. 6.9.2 South America Furazolidone Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Furazolidone Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Furazolidone Sales Value Share by Country, 2025 VS 2032
7 Furazolidone Country-level Sales and Value Analysis
  1. 7.1 Global Furazolidone Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Furazolidone Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Furazolidone Sales by Country (2021-2032)
  4. 7.3.1 Global Furazolidone Sales by Country (2021-2026)
  5. 7.3.2 Global Furazolidone Sales by Country (2027-2032)
  6. 7.4 Global Furazolidone Sales Value by Country (2021-2032)
  7. 7.4.1 Global Furazolidone Sales Value by Country (2021-2026)
  8. 7.4.2 Global Furazolidone Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Furazolidone Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Furazolidone Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Furazolidone Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Furazolidone Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Furazolidone Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Furazolidone Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Furazolidone Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Furazolidone Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Furazolidone Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Furazolidone Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Furazolidone Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Furazolidone Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Furazolidone Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Furazolidone Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Furazolidone Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Furazolidone Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Furazolidone Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Furazolidone Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Furazolidone Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Furazolidone Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Furazolidone Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Furazolidone Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Furazolidone Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Furazolidone Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Furazolidone Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Furazolidone Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Furazolidone Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Furazolidone Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Furazolidone Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Furazolidone Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Furazolidone Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Furazolidone Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Furazolidone Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Furazolidone Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Furazolidone Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Furazolidone Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Furazolidone Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Furazolidone Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Furazolidone Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Furazolidone Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Furazolidone Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Furazolidone Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Furazolidone Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Furazolidone Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Furazolidone Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Furazolidone Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Furazolidone Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Furazolidone Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Furazolidone Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Furazolidone Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Furazolidone Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Furazolidone Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Furazolidone Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Furazolidone Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Furazolidone Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Furazolidone Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Furazolidone Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Furazolidone Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Furazolidone Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Furazolidone Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Furazolidone Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Furazolidone Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Furazolidone Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Furazolidone Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Furazolidone Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Furazolidone Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Furazolidone Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Furazolidone Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Furazolidone Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Furazolidone Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Furazolidone Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Furazolidone Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Furazolidone Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Furazolidone Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Furazolidone Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Furazolidone Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Furazolidone Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Furazolidone Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Furazolidone Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Furazolidone Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Furazolidone Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Furazolidone Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Furazolidone Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Furazolidone Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Becton, Dickinson and Company (BD)
  2. 8.1.1 Becton, Dickinson and Company (BD) Company Information
  3. 8.1.2 Becton, Dickinson and Company (BD) Business Overview
  4. 8.1.3 Becton, Dickinson and Company (BD) Furazolidone Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Becton, Dickinson and Company (BD) Furazolidone Product Portfolio
  6. 8.1.5 Becton, Dickinson and Company (BD) Recent Developments
  7. 8.2 Daiichi Sankyo
  8. 8.2.1 Daiichi Sankyo Company Information
  9. 8.2.2 Daiichi Sankyo Business Overview
  10. 8.2.3 Daiichi Sankyo Furazolidone Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Daiichi Sankyo Furazolidone Product Portfolio
  12. 8.2.5 Daiichi Sankyo Recent Developments
  13. 8.3 Ferring
  14. 8.3.1 Ferring Company Information
  15. 8.3.2 Ferring Business Overview
  16. 8.3.3 Ferring Furazolidone Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Ferring Furazolidone Product Portfolio
  18. 8.3.5 Ferring Recent Developments
  19. 8.4 Geo-Med
  20. 8.4.1 Geo-Med Company Information
  21. 8.4.2 Geo-Med Business Overview
  22. 8.4.3 Geo-Med Furazolidone Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Geo-Med Furazolidone Product Portfolio
  24. 8.4.5 Geo-Med Recent Developments
  25. 8.5 GrÜNenthal Gmbh
  26. 8.5.1 GrÜNenthal Gmbh Company Information
  27. 8.5.2 GrÜNenthal Gmbh Business Overview
  28. 8.5.3 GrÜNenthal Gmbh Furazolidone Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 GrÜNenthal Gmbh Furazolidone Product Portfolio
  30. 8.5.5 GrÜNenthal Gmbh Recent Developments
  31. 8.6 Keyfarm
  32. 8.6.1 Keyfarm Company Information
  33. 8.6.2 Keyfarm Business Overview
  34. 8.6.3 Keyfarm Furazolidone Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Keyfarm Furazolidone Product Portfolio
  36. 8.6.5 Keyfarm Recent Developments
  37. 8.7 KPL Pharma
  38. 8.7.1 KPL Pharma Company Information
  39. 8.7.2 KPL Pharma Business Overview
  40. 8.7.3 KPL Pharma Furazolidone Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 KPL Pharma Furazolidone Product Portfolio
  42. 8.7.5 KPL Pharma Recent Developments
  43. 8.8 Marvi
  44. 8.8.1 Marvi Company Information
  45. 8.8.2 Marvi Business Overview
  46. 8.8.3 Marvi Furazolidone Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Marvi Furazolidone Product Portfolio
  48. 8.8.5 Marvi Recent Developments
  49. 8.9 Standpharm
  50. 8.9.1 Standpharm Company Information
  51. 8.9.2 Standpharm Business Overview
  52. 8.9.3 Standpharm Furazolidone Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Standpharm Furazolidone Product Portfolio
  54. 8.9.5 Standpharm Recent Developments
  55. 8.10 Teva
  56. 8.10.1 Teva Company Information
  57. 8.10.2 Teva Business Overview
  58. 8.10.3 Teva Furazolidone Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Teva Furazolidone Product Portfolio
  60. 8.10.5 Teva Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Furazolidone Value Chain Analysis
  2. 9.1.1 Furazolidone Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Furazolidone Sales Mode & Process
  6. 9.2 Furazolidone Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Furazolidone Distributors
  9. 9.2.3 Furazolidone Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research